Reverse Voxsplaining: Brand-Name Drugs

A strong, idea-dense health-economics essay (the 'reverse voxsplaining' series) replying to Vox/Sarah Kliff on EpiPen and drug pricing. Key distinction: generic overpricing is a regulatory failure, but brand-name overpricing is a DELIBERATE R&D-incentive trade (the patent monopoly). A lit review (8.5 studies finding price regulation cuts drug innovation vs 0.5 against) + RAND's analysis (price controls -> modest short-term savings but long-term life-expectancy losses) feeds his provocative Fermi estimate that US brand-name price controls could cost ~1 billion life-years — narrowly edging out Mao's Great Leap Forward as 'Worst Thing Ever.' The constructive half: most gains come from switching brand-name -> generic (Harvoni $32k -> ~$100), and the Pristiq-vs-Effexor scam (a slightly-worse me-too drug at 15x the price, prescribed because of pharma free lunches). Self-flagged uncertain on the economics (not a shaky-social-psych caveat).

Quality 77 · Excellent. A strong, idea-dense health-economics essay: the generic-vs-brand distinction, the price-controls-vs-innovation life-years analysis (with the memorable 'Worst Thing Ever' Fermi framing), and the concrete Pristiq me-too exposé. High-Strong/low-Excellent.

Claude’s paradigm shift 50 · Moderate. Low-Major-shift. The generic-vs-brand distinction + the price-controls-vs-innovation framing + the me-too-drug exposé are a sharp synthesis built on existing health economics.

Real-world impact 3 · Moderate. Moderate (3) — an influential health-economics essay; the price-controls-hurt-innovation argument and the me-too-drug critique reached real discourse.